Predicting ABPA Recurrence Using Blood and Immune Markers
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Confirmed diagnosis of ABPA (allergic bronchopulmonary aspergillosis) according to 2024 medical guidelines
- No active cancer or severe heart, kidney, brain, or lung damage
- No active tuberculosis, lung cancer, advanced heart failure, kidney failure, or severe liver disease
- Not pregnant or breastfeeding
- Not on long-term oral steroids or immunosuppressive medications, and no HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a computer model to see if it can predict when ABPA (a lung condition) might come back. If you have ABPA and are stable after treatment, this could help doctors monitor you better.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
This study looks at why some people with asthma get a lung infection from mold called aspergillus. It will help doctors better understand the condition and how to treat it.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study looks at how the immune system works and how well diseases like asthma, COPD, and others are controlled. You may join if you have one of these conditions or if you are a healthy volunteer or smoker without lung disease.
Hear when a new Allergic Bronchopulmonary Aspergillosis (ABPA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.